Long-term Beta-blocker Therapy After Acute Myocardial Infarction
Condition(s) studied
Investigational drug(s) / intervention(s)
Discontinuation of β-blocker: Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
Study summary
The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI).
Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.
Eligibility
Primary outcome measure(s)
- Major adverse cardiac events — 2.5 years after last patient enrollment
a composite of all-cause death, myocardial infarction, hospitalization for heart failure
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Samsung Medical Center | Seoul | South Korea | Recruiting |
More Samsung Medical Center trials in South Korea
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04769362 on ClinicalTrials.gov ↗ ← All trials in South Korea